The quantity of tumor-infiltrating lymphocytes (TIL score) is a prognostic factor for improved patient survival in triple-negative and HER2-positive breast tumor subtypes, and a predictor of response to anti-HER2 therapeutic antibodies in HER2-positive tumors [7, 26, 27]. This evidence concerns the gene ERBB2 and neoplasm.